title: The effects of nitric oxide on prostanoid production and release by human umbilical vein endothelial cells.
abstract: Human umbilical vein endothelial cells (HUVEC) express and synthesize both constitutive and inducible nitric oxide synthase (NOS) and cyclo-oxygenase (COX) enzymes, and have been extensively used as an in vitro model to investigate the role of these enzymes in the patho-physiology of placenta-fetal circulation. In this study we investigated the role of NO in regulating prostanoid production and release from HUVEC. Both untreated and IL-1beta-treated HUVEC were exposed to various NOS inhibitors and NO donors in short-term (1 or 3 hours) experiments, and the effects on prostanoid production were evaluated through the measurement of prostaglandins (PG) I2, E2 and F2alpha released in the incubation medium. We found that the inhibition of inducible NOS but not endothelial NOS antagonizes the IL-1beta-induced increase in PGI2 release. However, NOS inhibitors do not modify baseline PGI2 production. Pharmacological levels of NO, obtained with various NO donors, inhibit basal and IL-1beta-stimulated PG release.
authors.affiliation: Department of Obstetrics and Gynecology, Catholic University Medical School, Largo Francesco Vito 1, 00168 Rome, Italy.
authors.forename: Fiorella
authors.initials: F
authors.lastname: Miceli
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Tringali
authors.forename: Anna
authors.initials: A
authors.lastname: Tropea
authors.forename: Francesca
authors.initials: F
authors.lastname: Minici
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Orlando
authors.forename: Antonio
authors.initials: A
authors.lastname: Lanzone
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Navarra
authors.forename: Rosanna
authors.initials: R
authors.lastname: Apa
mesh_terms: D002478:Cells, Cultured; D015237:Dinoprost / Q000096:biosynthesis; D015232:Dinoprostone / Q000096:biosynthesis; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D011464:Epoprostenol / Q000096:biosynthesis / Q000494:pharmacology; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology; D008981:Molsidomine / Q000494:pharmacology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000494:pharmacology*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D052250:Nitric Oxide Synthase Type III; D009599:Nitroprusside / Q000494:pharmacology; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011453:Prostaglandins / Q000096:biosynthesis*; D011863:Radioimmunoassay; D014471:Umbilical Veins / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D004791:Enzyme Inhibitors; D007375:Interleukin-1; D020030:Nitric Oxide Donors; D011453:Prostaglandins; D014665:Vasodilator Agents; D009599:Nitroprusside; D009569:Nitric Oxide; D015237:Dinoprost; D008981:Molsidomine; D011464:Epoprostenol; C496314:NOS3 protein, human; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; D011451:Prostaglandin-Endoperoxide Synthases; D015232:Dinoprostone; D019331:NG-Nitroarginine Methyl Ester